$1.62
-0.04-2.41%
Can Fite Biopharma (CANF) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | H1 '26 | H1 '25 | H1 '24 | Q4 '23 | FY '25 | FY '24 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||||
| Estimate | $-1.43 | $-2.80 | $-0.40 | $-0.26 | $-10.40 | — |
| Actual | $-1.24 | $0.00 | $0.00 | $-0.01 | $-5.97 | $0.00 |
| Surprise | +13.3% | +100.0% | +100.0% | +96.2% | +42.6% | — |
| Revenue | ||||||
| Estimate | — | — | $150000 | $100000 | $202000 | $500000 |
| Actual | $202000 | $202000 | $316000 | $155000 | $405000 | $674000 |
| Surprise | — | — | +110.7% | +55.0% | +100.5% | +34.8% |
| Metric | FY '26E |
|---|---|
| Earnings Per Share (Non-GAAP) | |
| Consensus | $-2.04 |
| Revenue | |
| Consensus | $403200 |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| H1 | Sep 8, 2026 | $-1.24 | $-1.43 | 13.3 % |
| FY | Mar 26, 2026 | $-5.97 | $-10.40 | 42.6 % |
| H1 | Aug 28, 2025 | $0 | $-2.80 | 100.0 % |
| H1 | Aug 29, 2024 | $0 | $-0.40 | 100.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| FY | Mar 26, 2026 | $405.00K | $202.00K | 100.5 % |
| FY | Apr 14, 2025 | $674.00K | $500.00K | 34.8 % |
| H1 | Aug 29, 2024 | $316.00K | $150.00K | 110.7 % |
| Q4 | Mar 28, 2024 | $155.00K | $100.00K | 55.0 % |